BACKGROUND: The management of locally advanced @entity150 remains controversial with poor local control with radiotherapy alone. Synchronous chemotherapy regimens have yielded encouraging results in other primary sites. @entity1 AND METHODS: @entity1 with T2-T4a N0/NX M0 @entity150 were entered into this single centre phase I-II study. @entity1 received radiotherapy to 55 Gy in 20 fractions over four weeks. Concurrent chemotherapy was given with @entity1138 12 mg/m2 day 1 and @entity1487 500 mg/m2/24 hours weeks one and four of radiotherapy for five or seven days on each occasion. RESULTS: Thirty-one @entity1 entered the trial from March 1998 to December 1999 (22: 5-day; 9: 7-day schedule). Median age was 68 (range 58-79) years, 23 males and 8 females. T2: 9 (29%); T3a: 4 (12%); T3b: 9 (29%); T4: 9 (29%); TCC grade 2: 8 (26%) and grade 3: 23 (74%); 14 of 31 had @entity3041 . Ten of thirty-one had a GFR < 50 ml/min. @entity137 was mild to moderate with the five-day schedule. More severe @entity137 was seen with the seven-day schedule: five of nine @entity1 failed to complete planned therapy. Pathological complete response rate at three months was 74% (5-day regimen) and 50% (7-day regimen). Overall 12-month survival was 65%. CONCLUSION: Chemoradiotherapy with the five-day schedule is feasible with acceptable @entity137 in poor prognosis @entity1 . A randomised trial is being launched.

A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['Mitomycin C'] @entity3041 :: ('MESH:D006869', 'Disease') :: ['hydronephrosis'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity150 :: (MESH:D001749,Disease) :: ['bladder cancer']
